Industry News
Share your love
Ophthalmic Drug Delivery Summit 2024
In January, over 60 world-renowned experts in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit. This industry-focused event aims to advance effectiveness, durability, and minimally invasive techniques in retinal drug delivery. Key…
Reducing the Carbon Footprint of Intravitreal Injections
Adopting specific treatment protocols, minimizing travel for patients and staff, and reducing unnecessary use of personal protective equipment (PPE) can significantly decrease the carbon footprint of intravitreal injections. This topic was discussed in detail by Redmer van Leeuwen, MD, PhD,…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…
EPOMEC 2024: Ophthalmology Conference Highlights
The Evolving Practice of Ophthalmology Middle East Conference (EPOMEC) is set to take place from December 5–7, 2024, at the Dubai World Trade Centre, United Arab Emirates. This prestigious event brings together the latest advancements in ophthalmology from across the…
ONS-5010 Falls Short in NORSE EIGHT Trial for Wet AMD
ONS-5010 (LYTENAVA), an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (AMD), failed to meet the noninferiority endpoint in the NORSE EIGHT clinical trial, according to preliminary topline results announced by Outlook Therapeutics. About the NORSE EIGHT Trial…
Avirmax Launches ABI-110 Gene Therapy Trial for Wet AMD
Avirmax Biopharma has reached a major milestone in its mission to revolutionize the treatment of wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) by successfully dosing the first patient in the phase I/IIa clinical trial of ABI-110, the…
CHMP Endorses FYB203: Aflibercept Biosimilar Approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept. This development marks a significant milestone in expanding affordable…
USC Receives $6M Grant for Dry AMD Therapy
The California Institute for Regenerative Medicine (CIRM) has awarded a $6 million, two-year grant to researchers at the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute. This funding will advance preclinical studies…